IOP elevation after STTA by Maeda, Yuki et al.
RESEARCH ARTICLE
Intraocular pressure elevation after subtenon
triamcinolone acetonide injection; Multicentre
retrospective cohort study in Japan
Yuki Maeda1,2, Hiroto IshikawaID1,2*, Hiroki Nishikawa3, Miho Shimizu1,4,
Takamasa KinoshitaID1,4, Rie Ogihara1,5, Shigehiko Kitano1,5, Chihiro Yamanaka1,6,
Yoshinori Mitamura1,6, Masahiko Sugimoto1,7, Mineo Kondo1,7, Yoshihiro Takamura1,8,
Nahoko Ogata1,9, Tomohiro Ikeda1,2, Fumi Gomi1,2
1 J-CREST (Japan Clinical REtina STudy group), Kagoshima, Japan, 2 Department of Ophthalmology,
Hyogo College of Medicine, Nishinomiya, Japan, 3 Center for Clinical Research and Education, Hyogo
College of Medicine, Nishinomiya, Japan, 4 Department of Ophthalmology, Sapporo City General Hospital,
Sapporo, Japan, 5 Department of Ophthalmology, Diabetes Center, Tokyo Women’s Medical University
School of Medicine, Shinjuku-ku, Japan, 6 Department of Ophthalmology, Tokushima University, Tokushima,
Japan, 7 Department of Ophthalmology, Mie University, Tsu, Japan, 8 Department of Ophthalmology, Fukui
University, Yoshida, Japan, 9 Department of Ophthalmology, Nara Medical University School of Medicine,
Kashihara, Japan
* ohmyeye@gmail.com
Abstract
Purpose
To evaluate real-world evidence for intraocular pressure (IOP) elevation after subtenon tri-
amcinolone acetonide injection (STTA) in 1252 Japanese patients (1406 eyes) in the Japan
Clinical REtina STudy group (J-CREST).
Methods
This was a multicentre retrospective study of the medical records of 1252 patients (676 men
(758 eyes); mean age: 63.8 ± 12.9 years) who received STTA in participating centres
between April 2013 and July 2017.
Results
IOP elevation was observed in 206 eyes (14.7%) and IOP increase� 6 mmHg was found in
328 eyes (23.3%). In total, 106 eyes (7.5%) needed medication and two eyes (0.14%)
needed surgical procedures. Younger age, higher baseline IOP, and steroid dose were risk
factors associated with IOP elevation. Risk factors associated with IOP increase� 6 mmHg
were younger age, lower baseline IOP, steroid dose, and higher incidences of diabetic mac-
ular oedema (DME) and uveitis. In contrast, with steroid dose fixed at 20 mg, a lower inci-
dence of DME was a risk factor for increased IOP, suggesting that STTA had dose-
dependent effects on IOP increase, especially in patients with DME.
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Conclusion
Our real-world evidence from a large sample of Japanese patients who received STTA
showed that the incidence of IOP elevation after STTA was 14.7%, and was associated with
younger age, higher baseline IOP, and steroid dose. Thus, IOP should be monitored, espe-
cially in patients with younger age, higher baseline IOP, and higher incidences of DME and
uveitis.
Introduction
Subtenon triamcinolone acetonide injection (STTA) was initially reported as treatment for
optic neuritis [1], and has been used to treat diabetic macular oedema (DME) [2–10], cystoid
macular oedema (CME) due to retinal vein occlusion (RVO) [11–13], uveitis [14–17], scleritis
[18, 19], neuroretinitis [20], and CME following intraocular surgery [21]. Previous studies
have shown that intravitreal triamcinolone acetonide injection (IVTA) is effective in patients
with DME [22], CRVO [23], and BRVO [24]; however, endophthalmitis after IVTA was
reported in rare cases [25]. In addition, two studies revealed that intraocular pressure (IOP)
elevation was observed in 33%–50% and 59%–83% of patients who received IVTA [26, 27].
The risk of severe side effects due to STTA is presumably lower than the risk due to IVTA [4];
moreover, the STTA technique is easier than the IVTA technique. Therefore, Japanese oph-
thalmologists commonly choose STTA as initial treatment for both DME and RVO. The inci-
dence of side effects is lower after STTA than after IVTA; however, side effects after STTA
include IOP elevation, cataract formation [28], and central serous chorioretinopathy [29].
Steroid-induced IOP elevation was first described in the 1950s, with IOP surveillance fol-
lowing administration of systemic steroids [30, 31]. Potential complications of STTA, such as
IOP elevation, were described in the 1970s [32]; this problem was discussed very actively in the
1990s [16, 33]. The presence of uveitis, younger patient age, and higher baseline IOP have
been identified as risk factors for IOP elevation following STTA [34–37]; however, studies thus
far have shown heterogeneous results and there is no consensus. The purpose of this study was
to perform an analysis of real-world evidence in Japanese patients who exhibited IOP elevation
following STTA, to determine the incidence of IOP elevation in relation to patient
characteristics.
Materials and methods
Study design and eligibility
This was a multicentre retrospective study involving the following institutions (J-CREST):
Hyogo College of Medicine, Sapporo City General Hospital, Tokyo Women’s Medical Univer-
sity School of Medicine, Tokushima University, Tsukuba University, Mie University, Fukui
University, and Nara Medical University School of Medicine. Between April 2013 and July
2017, a total of 1252 patients who received STTA were enrolled at the participating institu-
tions. The current study was performed in accordance with the Declaration of Helsinki and
with approval from the ethics committee of Hyogo College of Medicine (2421) and the ethics
committees of the other participating hospitals.
Patients
At each hospital in the J-CREST group, patients who received STTA were analysed using data
from medical records. The observation period after STTA was > 6 months for all analysed
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subjects. Exclusion criteria for this study were: 1) existing glaucoma diagnosis and associated
medication; 2) baseline IOP> 21 mmHg; 3) any intraocular surgery except glaucoma surgery
within 6 months after STTA injection. A total of 1406 eyes were analysed in 1252 Japanese
patients who received STTA.
Subtenon triamcinolone acetonide injection (STTA)
STTA was performed as follows: 20 mg of triamcinolone acetonide (TA) was injected into the
subtenon space after topical anaesthesia. Based on each patient’s eye conditions, STTA was
performed at the discretion of each participating ophthalmologist; more than 90% of patients
received STTA 1 time (20 mg total), while the remaining patients received it up to 5 times (20
mg per injection)
Study protocol
Data were extracted from medical records in the various hospitals and sent to the data centre
in the Department of Ophthalmology, Hyogo College of Medicine. The analysed data were as
follows: age, sex, ratio of bilateral or unilateral STTA, baseline and highest IOP during follow-
up periods, causative diseases, incidence of IOP elevation, incidence of IOP increase� 6
mmHg, total dose of TA, and treatments for IOP elevation. Causative diseases were catego-
rized as DME, CME due to RVO, uveitis, and others. For analysis, patients were grouped on
the basis of bilateral or unilateral STTA, with or without IOP elevation, and with or without
IOP increase� 6 mmHg.
IOP measurements
IOP measurements were performed using a Goldman tonometer or non-contact type tonome-
ter in each hospital. IOP measurement in each patient was performed using the same device
throughout the study. Baseline IOP was defined as the most recent IOP before STTA; the high-
est IOP was defined as the highest IOP after STTA during the follow-up period. When IOP ele-
vation was observed, treatments (e.g., eye drops, oral medication, and surgery) were
performed at the discretion of each participating ophthalmologist. IOP elevation was defined
as IOP> 21 mmHg. IOP increase� 6 mmHg was also assessed as an additional measurement
of IOP [34, 38–40].
Study endpoints
The primary endpoint was the cumulative incidence of patients with IOP elevation (IOP > 21
mmHg) after STTA. The secondary endpoint was the incidence of patients with IOP
increase� 6 mmHg. In addition, this study compared patients with bilateral STTA and unilat-
eral STTA, patients with and without IOP elevation, and patients with and without IOP
increase� 6 mmHg. Risk factors for IOP elevation and IOP increase� 6 mmHg were investi-
gated based on the patients’ characteristics.
Statistical analyses
For continuous variables, the mean, standard deviation, median, and range were calculated.
For discrete variables, the number of values in each category and the percentages in each cate-
gory were calculated. To assess group differences, the Wilcoxon signed-rank test were used for
continuous variables and Fisher’s exact test were used for categorical variables. Analyses were
performed with JMP1 Pro (version 14.0.0, SAS Institute Inc., Cary, NC, USA). For all
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analyses, p-values were reported, as were two-sided 95% confidence intervals for point esti-
mates. Differences with p< 0.05 were considered statistically significant.
Results
Patients’ demographics
The baseline characteristics in this study (1252 patients; 1406 eyes) and analyses of differences
between bilateral and unilateral STTA are shown in Table 1. Briefly, patient age (mean ± stan-
dard deviation) was 63.8 ± 12.9 years; the age of patients with bilateral STTA was significantly
younger than that of patients with unilateral STTA (p<0.0001, Wilcoxon signed-rank test). In
total, 686 patients were men (54.8%). In all patients, baseline IOP was 14.2 ± 3.1 mmHg and
the highest IOP during the follow-up period was 18.1 ± 5.0 mmHg. Causative diseases were
DME (632 eyes, 45.0%), RVO (457 eyes, 32.5%), uveitis (223 eyes, 15.9%), and others (94 eyes,
6.7%), including optic neuritis, thyroid-associated ophthalmopathy, and Irvine-Gass Syn-
drome. The highest IOP values in patients with DME, RVO, uveitis, and others were 18.2 ± 4.5
mmHg, 18.1 ± 5.4 mmHg, 18.1 ± 5.7 mmHg, and 17.3 ± 4.8 mmHg, respectively. The inci-
dences of DME and uveitis were significantly higher in patients with bilateral STTA than in
patients with unilateral STTA (p<0.0001, Fisher’s exact test). Sex, baseline and highest IOP,
incidence of IOP elevation, and incidence of IOP increase� 6 mmHg were not associated
with bilateral STTA.
Primary endpoint: IOP elevation (IOP > 21 mmHg)
Analyses of IOP elevation are shown in Table 2. Briefly, the incidence of IOP elevation
(IOP > 21 mmHg) was 14.7% (206 eyes). The average interval between the last STTA and
observation of IOP elevation was 77.4 ± 65.0 days (range: 1–405 days). The age in patients with
IOP elevation was significantly younger than that in patients without IOP elevation
(p<0.0001, Wilcoxon signed-rank test). Baseline and highest IOP, as well as total steroid dose,
were significantly higher in patients with IOP elevation than in patients without IOP elevation
(each p<0.0001, Wilcoxon signed-rank test). For treatments in patients with IOP elevation,
eye drops were administered in 106 eyes (51.5% of eyes with IOP elevation, 7.5% of all eyes)
Table 1. Patient characteristics.
Total Patients with bilateral STTA Patients with unilateral STTA P-value
Number of patients 1252 patients; 1406 eyes 154 patients; 308 eyes 1098 patients; 1098 eyes
Age 63.8 ± 12.9 years 61.2 ± 12.6 years 64.6 ± 12.9 years <0.0001
Sex (male) 686 (54.8%) 82 (53.3%) 594 (54.1%) 0.84
Baseline IOP 14.2 ± 3.1 mmHg 14.3 ± 2.9 mmHg 14.2 ± 3.1 mmHg 0.63
Highest IOP 18.1 ± 5.0 mmHg 17.9 ± 4.3 mmHg 18.1 ± 5.2 mmHg 0.71
Incidence of IOP elevation 206/1406 eyes
(14.7%)
37/308 eyes
(12.0%)
169/1098 eyes
(15.4%)
0.14
Incidence of IOP increase� 6 mmHg 328/1406 eyes
(23.3%)
70/308 eyes
(22.7%)
258/1098 eyes
(23.5%)
0.78
Causative diseases
DME 632 eyes (45.0%) 190 eyes (61.7%) 442 eyes (40.3%) <0.0001
RVO 457 eyes (32.5%) 29 eyes (9.4%) 428 eyes (39.0%)
Uveitis 223 eyes (15.9%) 76 eyes (24.7%) 147 eyes (13.4%)
Others 94 eyes (6.7%) 13 eyes (4.2%) 81 eyes (7.4%)
DME, diabetic macular oedema; IOP, intraocular pressure; RVO, retinal vein occlusion; STTA, subtenon triamcinolone acetonide injection
https://doi.org/10.1371/journal.pone.0226118.t001
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and glaucoma surgery was performed in two eyes (1.0% of eyes with IOP elevation, 0.14% of
all). After treatment, IOP returned to normal in patients who had exhibited IOP elevation. Sex
and causative diseases were not associated with IOP elevation.
Secondary endpoint: IOP increase> 6 mmHg
Analyses of IOP increase� 6 mmHg are shown in Table 3. Briefly, the incidence of IOP
increase� 6 mmHg was 23.3% (328 eyes). The age of patients with IOP increase� 6 mmHg
was significantly younger than that of patients with IOP increase < 6 mmHg (p<0.0001, Wil-
coxon signed-rank test). Baseline and highest IOP, total steroid dose, and the incidence of IOP
elevation were significantly higher in patients with IOP increase� 6 mmHg than in patients
with IOP increase < 6 mmHg (each p<0.0001, Wilcoxon signed-rank test). As causative dis-
eases, the incidences of DME and uveitis were significantly higher in patients with IOP
increase� 6 mmHg than in patients with IOP increase < 6 mmHg (p = 0.02, Fisher’s exact
test). For treatments in patients with IOP increase� 6 mmHg, eye drops were administered in
95 eyes (29.0% of eyes with IOP increase > 6 mmHg, 6.8% of all eyes) and glaucoma surgery
was performed in two eyes (1.2% of eyes with IOP increase� 6 mmHg, 0.14% of all eyes).
After treatment, IOP returned to normal in patients who had exhibited IOP increase� 6
mmHg. Sex was not associated with IOP increase� 6 mmHg.
Other endpoints
Regarding causative diseases, the incidences of IOP elevation (IOP > 21 mmHg) and IOP
increase� 6 mmHg in patients with DME, RVO, uveitis, and others are shown in Tables 2
and 3, respectively. No causative diseases were associated with IOP elevation (p = 0.64, Fisher’s
exact test); however, the incidences of DME and uveitis were significantly associated with IOP
increase� 6 mmHg (p = 0.02, Fisher’s exact test).
To assess risk factors for IOP elevation and IOP increase without the effect of steroid dose,
we analysed the data with a fixed steroid dose (TA = 20 mg) (Table 4). Similar to the findings
with a variable steroid dose, younger age and higher baseline IOP were associated with IOP
Table 2. Analyses of IOP elevation (IOP> 21 mmHg).
Total IOP elevation No IOP elevation P-value
Number of patients 1406 eyes 206 eyes (14.7%) 1200 eyes (85.3%)
Age 63.8 ± 12.9 years 57.6 ± 12.6 years 64.9 ± 12.7 years <0.0001
Sex (male) 686 (54.8%) 116 (56.3%) 642 (53.5%) 0.45
Baseline IOP 14.2 ± 3.1 mmHg 16.4 ± 2.5 mmHg 13.8 ± 3.0 mmHg <0.0001
Highest IOP 18.1 ± 5.0 mmHg 26.6 ± 6.2 mmHg 16.6 ± 2.9 mmHg <0.0001
Total steroid dose 20.5 ± 4.3 mg 23.3 ± 10.9 mg 20.0 ± 0.0 mg <0.0001
Causative diseases
DME 632 eyes (45.0%) 89 eyes (43.2%) 543 eyes (45.3%) 0.63
RVO 457 eyes (32.5%) 65 eyes (31.6%) 392 eyes (39.0%)
Uveitis 223 eyes (15.9%) 39 eyes (18.9%) 184 eyes (15.3%)
Others 94 eyes (6.7%) 13 eyes (6.3%) 81 eyes (6.8%)
Treatments
Eye drops 106 eyes (51.5% of eyes with IOP elevation; 7.5% of all eyes) 0 eyes <0.0001
Glaucoma surgery 2 eyes (1.0% of eyes with IOP elevation; 0.14% of all eyes) 0 eyes
DME, diabetic macular oedema; IOP, intraocular pressure; RVO, retinal vein occlusion
https://doi.org/10.1371/journal.pone.0226118.t002
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elevation. In addition, IOP increase� 6 mmHg was associated with younger age, lower base-
line IOP, higher incidence of uveitis, and lower incidence of DME.
Discussion
In this study, we analysed the proportions of eyes with IOP elevation after STTA in a sample of
more than 1,000 Japanese patients, and assessed the characteristics associated with IOP
Table 3. Analyses of IOP increase� 6 mmHg.
Total IOP increase� 6 mmHg IOP increase < 6 mmHg P-value
Number of patients 1406 eyes 328 eyes (23.3%) 1078 eyes (76.7%)
Age 63.8 ± 12.9 years 60.9 ± 14.0 years 64.7 ± 12.5 years <0.0001
Sex (male) 686 (54.8%) 191 (58.2%) 567 (52.6%) 0.07
Baseline IOP 14.2 ± 3.1 mmHg 13.5 ± 3.1 mmHg 14.4 ± 3.0 mmHg <0.0001
Highest IOP 18.1 ± 5.0 mmHg 23.0 ± 6.7 mmHg 16.6 ± 3.1 mmHg <0.0001
Total steroid dose 20.5 ± 4.3 mg 21.9 ± 8.6 mg 20.1 ± 1.1 mg <0.0001
Causative diseases
DME 632 eyes (45.0%) 135 eyes (41.2%) 497 eyes (32.8%) 0.02
RVO 457 eyes (32.5%) 103 eyes (31.4%) 354 eyes (39.0%)
Uveitis 223 eyes (15.9%) 70 eyes (21.3%) 153 eyes (14.2%)
Others 94 eyes (6.7%) 20 eyes (6.1%) 74 eyes (6.9%)
Incidence of IOP elevation 206 eyes 161 eyes (78.2%) 45 eyes (21.8%) <0.0001
Treatments
Eye drops 106 eyes 95 eyes (29.0% of eyes with IOP increase� 6 mmHg; 6.8% of all eyes) 11 eyes (1.0%) <0.0001
Glaucoma surgery 2 eyes 2 eyes (1.2% of eyes with IOP increase� 6 mmHg; 0.14% of all eyes) 0 eyes (0.0%)
DME, diabetic macular oedema; IOP, intraocular pressure; RVO, retinal vein occlusion
https://doi.org/10.1371/journal.pone.0226118.t003
Table 4. Analyses of IOP elevation and IOP increase with a fixed steroid dose (TA = 20 mg).
Total IOP elevation No IOP elevation P-value
Number of patients 1383 eyes 183 eyes (13.2%) 1200 eyes (86.8%)
Age 63.8 ± 12.9 years 57.1 ± 12.7 years 64.9 ± 12.7 years <0.0001
Baseline IOP 14.2 ± 3.1 mmHg 16.4 ± 2.5 mmHg 13.8 ± 3.0 mmHg <0.0001
Highest IOP 18.0 ± 4.9 mmHg 26.7 ± 6.4 mmHg 16.6 ± 2.9 mmHg <0.0001
Causative diseases
DME 626 eyes (45.3%) 83 eyes (45.4%) 543 eyes (45.3%) 0.38
RVO 443 eyes (32.0%) 51 eyes (27.9%) 392 eyes (32.7%)
Uveitis 220 eyes (15.9%) 36 eyes (19.7%) 184 eyes (15.3%)
Others 94 eyes (6.8%) 13 eyes (7.1%) 81 eyes (6.8%)
Total IOP increase� 6 mmHg IOP increase < 6 mmHg
Number of patients 308 eyes (22.3%) 1075 eyes (77.7%)
Age 57.1 ± 12.7 years 64.9 ± 12.7 years <0.0001
Baseline IOP 13.4 ± 3.1 mmHg 14.4 ± 3.0 mmHg <0.0001
Highest IOP 22.7 ± 6.8 mmHg 16.6 ± 3.1 mmHg <0.0001
Causative diseases
DME 129 eyes (41.9%) 497 eyes (46.2%) 0.01
RVO 91 eyes (29.6%) 352 eyes (32.7%)
Uveitis 68 eyes (22.1%) 152 eyes (14.1%)
Others 20 eyes (6.5%) 74 eyes (6.9%)
DME, diabetic macular oedema; IOP, intraocular pressure; RVO, retinal vein occlusion
https://doi.org/10.1371/journal.pone.0226118.t004
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elevation in those patients. IOP elevation and IOP increase� 6 mmHg were found 14.7% and
23.3% of patients who received STTA, respectively. These results are similar to the findings of
a prior study, in which IOP elevation (IOP > 21 mmHg) was observed in 10/62 eyes (16%) fol-
lowing treatment with dexamethasone eye drops [38]. In contrast, IOP elevation after treat-
ment with 4 mg IVTA was observed in 48/150 eyes (32%) [40] and 26/60 eyes (43%) [39].
As in the present study, IOP elevation after treatment with 20 mg STTA was observed in 7/
85 eyes (8.2%) [7] and 8/48 eyes (16.7%) [34]; IOP elevation after treatment with 40 mg STTA
was observed in 6/49 eyes (12%) [41], 6/35 eyes (17%) [5], and 26/115 eyes (22.6%) [42].
Prior studies comparing IVTA and STTA revealed no eyes with IOP elevation (IOP > 25
mmHg) and no significant differences in IOP between the two groups for during a 6 month
follow-up period [3]. Moreover, IVTA was reported to cause significantly higher IOP eleva-
tion, compared with that caused by STTA [4]. According to Inatani and colleagues, IOP
elevation > 24 mmHg was observed in 2.8%, 3.7%, and 13.5% of patients after treatment with
12 mg, 20 mg, and 40 mg STTA, respectively; they concluded that the risk of IOP elevation was
increased by TA treatment in a dose-dependent manner [35].
The mechanism of steroid-induced IOP elevation remains unclear. In electron microscopy-
based anatomical analyses of the trabecular meshwork in patients with steroid glaucoma who
underwent trabeculectomy, the trabecular meshwork exhibited morphological changes sec-
ondary to deposits of fibrillary elements and extracellular material; thus, the aqueous humour
route had become obstructed [43]. Reduced phagocytosis activity in trabecular meshwork cells
led to increased aqueous humour flow resistance [44]. Whereas some researchers reported an
association between the MYOC gene and steroid-induced glaucoma [45, 46], others reported no
such association [47, 48]. Finally, the MYOC genetic mutation was negatively associated with
steroid-induced glaucoma in a recent study [49].
When comparing patients with bilateral STTA and those with unilateral STTA, patients
with unilateral STTA were older and exhibited a higher incidence of RVO than patients with
bilateral STTA. This is reasonable because RVO is known to develop in elderly people. How-
ever, baseline and highest IOP, as well as the incidences of IOP elevation and IOP increase� 6
mmHg, were not associated with bilateral or unilateral STTA. Regarding risk factors for IOP
elevation, younger people are widely known to be at higher risk [34–37]. Moreover, DME and
uveitis contributed to IOP elevation in the present study, as previously reported. Yamamoto
and colleagues reported that the average age of patients who received STTA and exhibited
IOP< 24 mmHg was 65.8 years, while the average age of patients who received STTA and
exhibited IOP > 24 mmHg was 57.1 years. Baseline IOP values in these patients were 13.8
mmHg and 15.1 mmHg, respectively, suggesting that younger age and higher baseline IOP
were risk factors for IOP elevation [37]. The results from our study with a large number of
patients were similar; younger age and higher baseline IOP were risk factors for IOP elevation.
Regarding high baseline IOP, it is reasonable that IOP is elevated after STTA in patients with
higher baseline IOP; however, it remains unclear what is an appropriate IOP difference
between baseline and highest IOP after STTA. Patients with IOP increase� 6 mmHg after
STTA are classified as steroid responders [34, 50–52], suggesting that patients with low base-
line IOP are more frequently steroid responders. In addition, the risk factors for IOP
increase� 6 mmHg in our study were similar to those of prior studies: younger age, lower
baseline IOP, steroid dose, and higher incidences of DME and uveitis.
To assess risk factors for IOP elevation and IOP increase without the effect of steroid dose,
we analysed the data with a fixed steroid dose (TA = 20 mg). From the analyses of IOP eleva-
tion under the steroid fixed condition, the risk factors were same; younger age and higher
baseline IOP. Similar to the findings with a variable steroid dose, the risk factors for IOP
increase� 6 mmHg were younger age, lower baseline IOP, and higher incidence of uveitis.
IOP elevation after STTA
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However, a lower incidence of DME was identified as a risk factor with a fixed steroid dose,
whereas a higher incidence of DME was a risk factor under a variable steroid dose; this sug-
gested that IOP might increase in association with the dose of TA, especially in patients with
DME.
An absolute IOP elevation (i.e., IOP> 21 mmHg), rather than a relative difference in IOP
(i.e., IOP increase� 6 mmHg), is evaluated in clinical treatment. However, a relatively large
difference in IOP may induce an effect on ganglion cells. In the present study, 14.7% and
23.3% of all patients showed IOP elevation (IOP > 21 mmHg) and IOP increase� 6 mmHg
after STTA, respectively. In patients with IOP elevation, steroid dose was associated with IOP
elevation. This steroid dose-dependent elevation in IOP was previously reported [35]. There-
fore, patients who undergo multiple STTA treatments need strict IOP observation. Further-
more, patients who experienced subtenon overflow of TA developed IOP elevation at a high
rate after STTA [9]. Therefore, to prevent IOP elevation, it is necessary to perform STTA in a
precise manner.
We acknowledge several limitations to this study. First, the IOP measurement device was
not standardized among hospitals. However, IOP measurements in each patient were per-
formed with an identical device during the follow-up period, suggesting that the analysis of
IOP increase� 6 mmHg might have yielded more representative data than that produced by
analysis of IOP elevation. Second, the time to measure IOP was not standardized among hospi-
tals because our study was a retrospective multicentre study. However, this study included a
large number of patients, such that the respective risks of IOP elevation and increase are likely
to be accurate and representative.
In summary, we retrospectively examined the incidences of IOP elevation and IOP
increase� 6 mmHg in a large number of Japanese patients who received STTA. IOP elevation
and IOP increase� 6 mmHg were found in 14.7% and 23.3% of patients who received STTA,
respectively. The risk factors of IOP elevation were younger age, higher baseline IOP, and ste-
roid dose; risk factors of IOP increase� 6 mmHg were younger age, lower baseline IOP, ste-
roid dose, and higher incidences of DME and uveitis. Thus, in patients receiving STTA, IOP
should be closely monitored in those with younger age, higher baseline IOP, and higher inci-
dences of DME and uveitis.
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